{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:51:42Z","timestamp":1783529502116,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bladder cancer is the 10th most common cancer globally, with a growing incidence in Japan. Evaluation of molecular, genetic, and cellular biomarkers that predict treatment response and prognosis in patients with metastatic urothelial carcinoma (mUC) may help optimize sequential treatment strategies with chemotherapy and immune checkpoint inhibitors (ICIs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicenter, retrospective cohort study, evaluated programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and cancer-immune phenotype as predictive prognostic biomarkers following first-\/second-line treatment in Japanese adult patients with mUC. The primary endpoint was prevalence of PD-L1 expression. Secondary endpoints were TMB, overall survival (OS), and progression-free survival (PFS) from initiation of first-line treatment, and exploratory endpoints were cancer-immune phenotype, OS, PFS, and treatment response according to potential biomarker status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 143 patients included (mean age 71.7\u00a0years), PD-L1 expression was high in 29.4% of patients. Non-synonymous TMB was high in 33.6% and low in 66.4%. Cancer-immune phenotype was immune-desert in 62.9%, immune-excluded in 30.8%, and inflamed in 6.3%. Median OS and PFS following first-line treatment were 18.2 and 7.4\u00a0months, respectively. Overall response to second-line treatment was slightly better with high versus low\/negative PD-L1 expression. PD-L1 expression and TMB were non-significant predictors of OS or PFS, whereas immune-excluded phenotype was associated with better OS in comparison with immune-desert phenotype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PD-L1 expression and TMB were non-significant predictors of prognosis after first-line treatment in Japanese patients with mUC, but cancer-immune phenotype may be an important prognostic factor in chemotherapy-ICI sequential treatment strategies.<\/jats:p>\n                <jats:p><jats:italic>Clinical trial registration number<\/jats:italic> UMIN000037727.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-023-02386-y","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T09:02:08Z","timestamp":1690448528000},"page":"1398-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-596X","authenticated-orcid":false,"given":"Hiroyuki","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-4366","authenticated-orcid":false,"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-8379","authenticated-orcid":false,"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-7769","authenticated-orcid":false,"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuya","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Koto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-8878","authenticated-orcid":false,"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"3","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2386_CR2","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L (2020) The global burden of urinary bladder cancer: an update. World J Urol 38(8):1895\u20131904","journal-title":"World J Urol"},{"key":"2386_CR3","unstructured":"National Cancer Center (2021) Cancer registry and statistics, cancer information service, National Cancer Center, Japan. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html. Accessed November 2022"},{"issue":"10","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/iju.13376","volume":"24","author":"J Miyazaki","year":"2017","unstructured":"Miyazaki J, Nishiyama H (2017) Epidemiology of urothelial carcinoma. Int J Urol 24(10):730\u2013734","journal-title":"Int J Urol"},{"issue":"9","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H et al (2020) Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27(9):702\u2013709","journal-title":"Int J Urol"},{"key":"2386_CR6","unstructured":"Roupr\u00eat M, Babjuk M, Burger M et al (2021) European Association of Urology (EAU) Upper urinary tract urothelial cell carcinoma clinical guidelines. https:\/\/uroweb.org\/guideline\/upper-urinary-tract-urothelial-cell-carcinoma\/#1. Accessed June 2022"},{"issue":"4","key":"2386_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10147-018-1260-0","volume":"23","author":"T Yuasa","year":"2018","unstructured":"Yuasa T, Urakami S, Yonese J (2018) Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol 23(4):599\u2013607","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N et al (2021) Advances in bladder cancer biology and therapy. Nat Rev Cancer 21(2):104\u2013121","journal-title":"Nat Rev Cancer"},{"key":"2386_CR9","unstructured":"Merck & Co., Inc., Pfizer (2021) Anti-PD-L1 antibody Bavencio\u00ae (generic name: avelumab (genetical recombination)), additional approval for indications for locally advanced or metastatic urothelial cancer (in Japanese). https:\/\/www.merckgroup.com\/jp-ja\/press\/mbj\/2021\/210224_News_Release_Bavencio_JP.pdf. Accessed June 2022"},{"issue":"6","key":"2386_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970\u2013976","journal-title":"Ann Oncol"},{"issue":"11","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, De Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"1","key":"2386_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7(1):278","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.eururo.2020.01.003","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Madison R, Raggi D et al (2020) Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder. Eur Urol 77(4):548\u2013556","journal-title":"Eur Urol"},{"issue":"10064","key":"2386_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67\u201376","journal-title":"Lancet"},{"issue":"6","key":"2386_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126908","volume":"4","author":"M Yarchoan","year":"2019","unstructured":"Yarchoan M, Albacker LA, Hopkins AC et al (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4(6):e126908","journal-title":"JCI Insight"},{"issue":"7637","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321\u2013330","journal-title":"Nature"},{"issue":"7693","key":"2386_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"issue":"6","key":"2386_CR18","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471\u20131474","journal-title":"Ann Surg Oncol"},{"key":"2386_CR19","unstructured":"Ventana Medical Systems (2017) Ventana PD-L1 (SP263) assay in urothelial carcinoma interpretation guide. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/p160046c.pdf. Accessed June 2022"},{"issue":"1","key":"2386_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","volume":"53","author":"T Takahara","year":"2021","unstructured":"Takahara T, Murase Y, Tsuzuki T (2021) Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. Pathology 53(1):56\u201366","journal-title":"Pathology"},{"issue":"7528","key":"2386_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558\u2013562","journal-title":"Nature"},{"issue":"10031","key":"2386_CR22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909\u20131920","journal-title":"Lancet"},{"issue":"10236","key":"2386_CR23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arranz Arija J\u00c1, Bamias A et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395(10236):1547\u20131557","journal-title":"Lancet"},{"issue":"10122","key":"2386_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748\u2013757","journal-title":"Lancet"},{"issue":"7","key":"2386_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22(7):931\u2013945","journal-title":"Lancet Oncol"},{"issue":"12","key":"2386_CR26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D et al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 21(12):1574\u20131588","journal-title":"Lancet Oncol"},{"issue":"5","key":"2386_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541\u2013550","journal-title":"Nat Med"},{"issue":"8","key":"2386_CR28","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22(8):1865\u20131874","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02386-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:07:25Z","timestamp":1695960445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02386-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Nishiyama has received research funding support from Ono, Chugai, Bayer, Takeda Pharmaceutical and Astellas Pharma, and received advisory or consulting fees from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Chugai, Janssen, and Merck Sharp & Dohme (MSD), and participated in speakers' bureaus for Astellas Pharma, AstraZeneca, Chugai, and MSD. Dr. Tsuzuki has received honoraria for lectures from AstraZeneca and Chugai. Dr. Ohyama has received honoraria for lectures from Janssen, Astellas Pharma, Nippon Shinyaku, AstraZeneca, Bayer, BMS, and Chugai, received research funding support from AstraZeneca, Parexel International, Ono, and MSD, and received grants from Sanofi, Nippon Shinyaku, Astellas, Ono, and Bayer. Dr. Matsuyama has received honoraria from Janssen Pharma, Chugai, Bayer, AstraZeneca, and MSD, and research funding support from Janssen Pharma, Chugai, Bayer, AstraZeneca, and MSD. Drs. Shinozaki, N Hayashi, Shin, Y Hayashi and Koto are employees of AstraZeneca K.K. and hold stocks of AstraZeneca PLC. Dr. Ogawa has received research funding support from Takeda, Nippon Shinyaku, AstraZeneca, and Bayer. All authors confirm that they have full control of all primary data and agree to allow the journal to review this data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by an independent ethical committee (Non-Profit Organization MINS Institutional Review Board, Approval ID: 190235). The study was reviewed and approved by the ethics committee in each site under the guidelines of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (promulgated on December 22, 2014 and partially revised on February 28, 2017). All patients included in the study provided written informed consent prior to study participation. In patients who had died or were lost to follow-up prior to registration, opt-out was applicable according to the ethical committee\/institutional review board\u2019s approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}]}}